StockNews.com Initiates Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report issued on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Price Performance

Shares of NASDAQ TCON opened at $0.03 on Friday. TRACON Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $14.75. The company’s fifty day moving average is $0.08 and its 200-day moving average is $0.50. The stock has a market cap of $89,001.00, a price-to-earnings ratio of 0.01 and a beta of 1.43.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.